Mission Statement, Vision, & Core Values (2026) of Shanghai RAAS Blood Products Co., Ltd.

Shanghai RAAS Blood Products Co., Ltd. (002252.SZ) stands at the intersection of compassion and biopharmaceutical rigor, tracing its roots to 1988 and becoming a publicly traded force on the Shenzhen Stock Exchange in 2008, with a mission defined as 'a cause for the heart and a passion for the country' that links plasma donors directly to patient outcomes; by July 2025 the company operates 5 production bases and 55 plasma donation centers across 11 provinces, carries honors like 'Shanghai Famous Trademark' and 'Shanghai Famous Brand,' and-after joining Haier Group's healthcare ecosystem in June 2024 and later terminating a planned major asset restructuring with Haier Biotech in January 2025-continues to emphasize core values of safety, quality, and efficacy, moral integrity, technological advancement, openness, and international collaboration (including ties with Grifols) as it seeks greater accessibility, stringent standards, and societal benefit through its human albumin, immunoglobulins, and coagulation factor portfolios.

Shanghai RAAS Blood Products Co., Ltd. (002252.SZ) - Intro

Shanghai RAAS Blood Products Co., Ltd. (002252.SZ) is a leading Chinese manufacturer specializing in blood-derived products - notably human albumin, immunoglobulins, and coagulation factors. Founded in 1988 and listed on the Shenzhen Stock Exchange in 2008, the company has built a broad product portfolio, an integrated quality management system, and a growing national footprint.

• Established: 1988; Shenzhen Stock Exchange listing: 2008 (ticker: 002252.SZ).
• Product focus: human albumin, intravenous immunoglobulins (IVIG), coagulation factors, and related plasma-derived therapies.
• Quality recognition: awarded titles including 'Shanghai Famous Trademark' and 'Shanghai Famous Brand'.

Key operational footprint (as of July 2025):

Mission

• Deliver safe, high-quality plasma-derived medicines that meet urgent clinical needs nationwide.
• Ensure a reliable plasma supply through responsible donor programs and operational excellence.
• Promote patient-centered innovation while maintaining rigorous regulatory compliance and traceability.

Vision

• Be China's most trusted plasma-derived therapeutics provider, expanding access to critical biologics.
• Integrate advanced manufacturing and quality systems to support stability and scalability in supply.
• Contribute to public health resilience through sustainable plasma sourcing and community engagement.

Core Values

• Safety first - uncompromising product safety and donor protection.
• Quality-driven - continuous improvement and adherence to international GMP and regulatory standards.
• Integrity - transparent governance, ethical sourcing, and accountability to patients and stakeholders.
• Innovation - process and product development to address unmet clinical needs.
• Collaboration - partnerships across healthcare, research, and community for systemic impact.

Milestones & Strategic Context

• 1988 - Company founded, beginning plasma-derived product development.
• 2008 - Public listing on Shenzhen Stock Exchange (002252.SZ), enabling capital access for expansion.
• By July 2025 - Expanded to 5 production bases and 55 plasma donation centers across 11 provinces.
• June 2024 - Integrated into Haier Group's healthcare ecosystem to augment capabilities and cross-industry collaboration.
• January 2025 - Opted to terminate a planned major asset restructuring with Haier Biotech and continue operations independently.

For an investor-focused profile and deeper market context, see: Exploring Shanghai RAAS Blood Products Co., Ltd. Investor Profile: Who's Buying and Why?

Shanghai RAAS Blood Products Co., Ltd. (002252.SZ) - Overview

Shanghai RAAS Blood Products Co., Ltd. (002252.SZ) articulates a mission that fuses compassion, national responsibility, and scientific advancement: 'a cause for the heart and a passion for the country.' This mission emphasizes the life-saving bridge between plasma donors and patients and positions the company as both a steward of public health and an innovator in blood-derived medicines.

• Core mission emphasis: linking donors and patients through safe, effective plasma-derived products that deliver societal benefit.
• Dual cultivation: internal-moral integrity, employee development, and quality-first culture; external-technological leadership, partner ecosystems, and regulatory alignment.
• Adaptation and inclusivity: commitment to remaining open to industry trends, policy shifts, and collaboration across public and private sectors to foster positive energy in the blood products industry.
• Holistic approach: compassion-driven patient focus integrated with sustained R&D investment to advance public health outcomes.

The company's mission is operationalized through strategic investments and measurable outputs that reflect both ethical stewardship and scientific capability.

Strategic priorities derived from the mission translate into measurable initiatives:

• Quality & safety: continuous upgrades in GMP facilities, cold chain logistics, and batch-release QC to ensure product safety for vulnerable patient populations.
• Technological advancement: scale-up of fractionation capacity, process yield optimization, and biologics formulation R&D to increase accessibility and therapeutic coverage.
• Ethical governance: donor care programs, transparent sourcing policies, and community outreach to sustain donor trust and social license to operate.
• Market & policy alignment: proactive engagement with regulators and hospitals to align product development with national essential medicine lists and reimbursement frameworks.

Key performance linkage between mission and outcomes (illustrative indicators):

• Percentage of revenue reinvested in R&D: ~5.6% (R&D expense / revenue)
• Gross margin stability: sustained by product mix weighted toward high-value immunoglobulins and albumin
• Donor-to-patient throughput: expansion of collection capacity targets to improve supply reliability

For investors and stakeholders seeking a deeper profile of the company's financials, ownership, and market positioning, see: Exploring Shanghai RAAS Blood Products Co., Ltd. Investor Profile: Who's Buying and Why?

Shanghai RAAS Blood Products Co., Ltd. (002252.SZ) - Mission Statement

• Core mission pillars: patient safety, product efficacy, regulatory compliance, and scalable national supply.
• Operational focus: expand plasma collection and production capacity while maintaining GMP and international quality alignment.
• Strategic posture: preserve operational independence but pursue ecosystem integration opportunities (e.g., 2024 Haier Group healthcare integration; restructuring with Haier Biotech terminated Jan 2025).

• Expand national accessibility: increase number and geographic reach of plasma donation centers and production bases to better serve China's clinical demand for plasma-derived therapies.
• Uphold safety and efficacy: keep stringent quality controls, emphasizing donor-screening, GMP-compliant manufacturing, and post-market surveillance to minimize infectious and product-risk profiles.
• Integrate with broader healthcare ecosystems: participate in industrial-health alliances (notably operative integration into Haier Group's healthcare ecosystem in 2024) to leverage distribution, R&D, and service synergies.
• Global alignment: deepen collaboration with international partners (e.g., Grifols) to adopt and benchmark against global quality and product standards.

• Quality & Safety: low adverse-event rates and compliance with NMPA and WHO standards; capital allocated to cold-chain, testing, and donor screening.
• Capacity growth: year-over-year plasma collection growth targeted in double digits (company disclosures cite multi-year expansion plans across 2022-2025).
• Profitability: gross margins supported by scale in plasma-derived fractionation and a product mix favoring high-margin immunoglobulins and albumin.
• R&D & partnerships: co-development and technology-transfer agreements (e.g., Grifols) to shorten product lifecycle and access advanced fractionation know-how.

Shanghai RAAS Blood Products Co., Ltd. (002252.SZ) - Vision Statement

Shanghai RAAS Blood Products Co., Ltd. (002252.SZ) envisions a future where safe, high-quality, and efficacious blood-derived medicines bridge the gap between donors and patients nationwide and internationally. The company's vision centers on building an integrated, ethically driven plasma ecosystem that combines advanced biomanufacturing, robust quality assurance, and societal responsibility to improve public health outcomes.

• Safety-first manufacturing and supply systems that meet and exceed national and international regulatory standards.
• Continuous technological advancement to optimize yield, purity, and therapeutic efficacy.
• Ethical stewardship of donor relationships and transparent community engagement.
• Open collaboration with healthcare institutions, research organizations, and regulators to broaden access to essential medicines.
• Inclusive organizational culture that fosters positive energy across the blood products industry.

Translating vision into measurable goals, Shanghai RAAS links strategy with concrete operational and financial targets to ensure alignment across R&D, production, and societal impact initiatives.

• Product safety: multi-stage viral inactivation/removal processes and batch release testing for each lot.
• Quality metrics: high batch-release pass rates and low recall incidence supported by statistical process control across production lines.
• Efficacy focus: ongoing clinical and real-world evidence generation for immunoglobulins and coagulation factor concentrates.

Core ethical and societal commitments are operationalized through programs that support donor welfare, patient assistance, and public-health partnerships. These initiatives are reflected in the company's capital allocation priorities-balancing investment in capacity expansion, quality control, and R&D.

• Openness & inclusiveness: partnerships with academic institutions, domestic hospitals, and international suppliers to accelerate technology transfer.
• Holistic impact: combining compassion for donors and patients with innovation to maximize public-health benefit per RMB invested.
• Governance: adherence to moral integrity in procurement, donor engagement, and distribution to maintain public trust.

For a focused analysis of Shanghai RAAS's recent financials and investor-relevant metrics, see: Breaking Down Shanghai RAAS Blood Products Co., Ltd. Financial Health: Key Insights for Investors